DMTK News and Press, DermTech Inc From 04/26/23

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a physician-founded, member-focused and community-based not-for-profit health plan in New ...

2023-04-14 15:21:48 ET Summary DermTech has designed a non-invasive sticky patch to test for melanoma. The product is potentially cheaper than current standards of care and more accurate. DermTech sees its patch as targeting a ~$2.5bn market and is targeting an annual revenue ...

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Thursday, May 4, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fir...

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a Blues plan in North Carolina. The contract, which is in addition to a favorable coverage...

2023-04-10 06:37:05 ET Summary My Q1 FY 2023 total returns was +18.8% vs. +2.8% for the Russell 2000. One of my top Buy and Hold positions, TravelCenters of America, was bought out by BP p.l.c., and this was a big positive driver of the outperformance. I discuss the Second Win...

Only 19% of respondents wear sunscreen year-round; Sun Regrets campaign provides education on the most common skin cancers and risks In a new survey of 1,000 millennials and 1,000 Gen Xers, 75% of respondents said that while they are mindful of their sun exposure, only 19% w...

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement with a Blues plan in Arizona. The agreement makes the foundational assay of the DermTech Melano...

DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that management is scheduled to present at the following investor conferences during March 2023. TD Co...

DermTech ( NASDAQ: DMTK ) was trading lower premarket on Friday despite Q4 results beating analysts' estimates, while the company announced that CEO John Dobak would step down. Net loss widened to -$28.22M, compared to -$26.05M in Q4 2021. Total revenue in Q4 declined -5.4% Y...

DermTech, Inc. (DMTK) Q4 2022 Earnings Conference Call March 2, 2023 05:00 PM ET Company Participants Steve Kunszabo - Head of IR John Dobak - President and CEO Kevin Sun - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Stephanie Y...